SCHEMBL18664451

SCHEMBL18664451

N#Cc1ccc(-c2ccc(O)cc2)c(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP3 P08254 1/20 0.57
CA12 O43570 1/20 0.52
CA2 P00918 1/20 0.52
CA3 P07451 1/20 0.52
CA6 P23280 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
ESR1 P03372 7/20 0.47
ESR2 Q92731 7/20 0.47
HSD17B1 P14061 1/20 0.42
HSD17B2 P37059 1/20 0.42
AR P10275 1/20 0.42
EGLN2 Q96KS0 3/20 0.40
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
KDM1A O60341 1/20 0.40
MAOA P21397 1/20 0.40
DGAT1 O75907 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18664403 0.89 MMP3 (0.57) MMP3CA12CA2CA3CA6
SCHEMBL17643479 0.85 AHR (0.47) EGLN2CYP11B1CYP11B2MAOADGAT1
SCHEMBL17629881 0.82 MAOB (0.43) AREGLN2CYP11B1CYP11B2KDM1A
SCHEMBL17629942 0.82 EGLN2 (0.49) AREGLN2CYP11B1CYP11B2KDM1A
SCHEMBL28022390 0.81 CSNK2A1 (0.49) CA2AREGLN2CYP11B1CYP11B2
SCHEMBL17629878 0.81 ENPP2 (0.56) MMP3CA2AREGLN2CYP11B1
SCHEMBL9348873 0.80 CYP11B1 (0.53) CA12CA2CA3CA6CA9
SCHEMBL4667162 0.80 ESR2 (0.59) MMP3CA12CA2CA3CA6
SCHEMBL31463157 0.79 MMP3 (0.47) MMP3CA12CA2CA9CYP11B2
SCHEMBL2786090 0.79 MMP3 (0.57) MMP3CA12CA2CA3CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11447501-B2 Biphenyl-containing diarylpyrimido compounds, pharmaceutically-acceptable salts thereof, composition and preparation thereof Fudan Univeristy (CN) 2022-09-20 US disclosed
EP-3349581-B1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2021-12-01 EP disclosed
EP-3349581-B1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2021-12-01 EP disclosed
US-20210040109-A1 BIPHENYL-CONTAINING DIARYLPYRIMIDO COMPOUNDS, PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF, COMPOSITION AND PREPARATION THEREOF FUDAN UNIVERSITY (CN) 2021-02-11 US disclosed
US-10766890-B2 Hepatitis B core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2020-09-08 US disclosed
US-10766890-B2 Hepatitis B core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2020-09-08 US disclosed
US-20180265484-A1 HEPATITIS B CORE PROTEIN MODULATORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2018-09-20 US disclosed
WO-2017048962-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES, INC. (US) 2017-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210040109-A1 BIPHENYL-CONTAINING DIARYLPYRIMIDO COMPOUNDS, PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF, COMPOSITION AND PREPARATION THEREOF CYP2C19, CYP2C9, CYP2B6 MMP3 4585/4885CA12 3025/4885CA2 1989/4885
US-20180265484-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS MMP3 4619/4885CA12 3562/4885CA2 4707/4885
US-11447501-B2 Biphenyl-containing diarylpyrimido compounds, pharmaceutically-acceptable salts thereof, composition and preparation thereof CYP2C19, CYP2C9, CYP2B6 MMP3 4585/4885CA12 3025/4885CA2 1989/4885
US-10766890-B2 Hepatitis B core protein modulators HAVCR2, FABP1, MAVS MMP3 4619/4885CA12 3562/4885CA2 4707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.